| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sarepta Therapeutics Inc (NASDAQ: SRPT)
SRPT Technical Analysis
5
| As on 9th Jun 2023 SRPT SHARE Price closed @ 127.67 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 88.60 & Strong Buy for SHORT-TERM with Stoploss of 78.25 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SRPTSHARE Price
| Open | 125.88 | Change | Price | % |
| High | 130.10 | 1 Day | 1.76 | 1.40 |
| Low | 125.49 | 1 Week | 4.07 | 3.29 |
| Close | 127.67 | 1 Month | 5.54 | 4.54 |
| Volume | 757400 | 1 Year | 36.54 | 40.10 |
| 52 Week High 157.19 | 52 Week Low 62.69 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SRPT Daily Charts |
SRPT Intraday Charts |
Whats New @ Bazaartrend |
SRPT Free Analysis |
|
|
SRPT Important Levels Intraday
| RESISTANCE | 136.55 |
| RESISTANCE | 133.70 |
| RESISTANCE | 131.94 |
| RESISTANCE | 130.18 |
| SUPPORT | 125.16 |
| SUPPORT | 123.40 |
| SUPPORT | 121.64 |
| SUPPORT | 118.79 |
SRPT Forecast April 2024
| 4th UP Forecast | 186.81 |
| 3rd UP Forecast | 167.84 |
| 2nd UP Forecast | 156.12 |
| 1st UP Forecast | 144.4 |
| 1st DOWN Forecast | 110.94 |
| 2nd DOWN Forecast | 99.22 |
| 3rd DOWN Forecast | 87.5 |
| 4th DOWN Forecast | 68.53 |
SRPT Weekly Forecast
| 4th UP Forecast | 141.60 |
| 3rd UP Forecast | 137.13 |
| 2nd UP Forecast | 134.37 |
| 1st UP Forecast | 131.61 |
| 1st DOWN Forecast | 123.73 |
| 2nd DOWN Forecast | 120.97 |
| 3rd DOWN Forecast | 118.21 |
| 4th DOWN Forecast | 113.74 |
SRPT Forecast2024
| 4th UP Forecast | 317.69 |
| 3rd UP Forecast | 256.75 |
| 2nd UP Forecast | 219.08 |
| 1st UP Forecast | 181.41 |
| 1st DOWN Forecast | 73.93 |
| 2nd DOWN Forecast | 36.26 |
| 3rd DOWN Forecast | -1.41 |
| 4th DOWN Forecast | -62.35 |
Sarepta Therapeutics Inc ( NASDAQ USA Symbol : SRPT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SRPT Business Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Address: 215 First Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service